PLK4
50 programs · 50 companies
Programs
50
Companies
50
Active Trials
30
Targeting PLK4
| Drug | Company | Phase | MOA | Indications |
|---|---|---|---|---|
| Bemanesiran | BioNTech | Phase 3 | ACCMDD | |
| Peminaritide | Sarepta | NDA/BLA | T2DPNH | |
| Pexaosocimab | United Therapeutics | NDA/BLA | HCCFTD | |
| Polalucimab | Jazz Pharma | Preclinical | ThymomaCKD | |
| ILM-2412 | Illumina | Phase 3 | HS | |
| ROI-3353 | Roivant Sciences | Phase 1/2 | ASCF | |
| SAG-8067 | Sage | NDA/BLA | Thymoma | |
| Motanesiran | Novavax | Phase 2/3 | HSNarcolepsy | |
| Ivozasiran | AbCellera | Phase 2 | ALL | |
| GLP-3342 | Galapagos | Phase 1/2 | MS | |
| Fixatapinarof | Jiangsu Hengrui | Preclinical | EoENB | |
| Rimatuximab | Boehringer Ingelheim | Phase 2/3 | MGFSGS | |
| SAM-IIT-777 | Samsung Medical Ctr | Phase 1 | Hemophilia A | |
| FRE-IIT-769 | Fred Hutch Cancer Ctr | Phase 2/3 | AML | |
| UCL-IIT-649 | UCLA Health | NDA/BLA | Melanoma | |
| GIM-IIT-993 | GIMEMA | NDA/BLA | FTD | |
| Elrazanubrutinib | CervoMed | NDA/BLA | PAH | |
| GYR-4594 | Gyre Ther | Preclinical | PsoriasisDLBCL | |
| FOR-4809 | Forma Therapeutics | Phase 1 | ASMCC | |
| Tiracilimab | Chimerix | Phase 1 | MDSALS | |
| Bemasertib | Achilles Therapeutics | Phase 1 | DravetCholangiocarcinoma | |
| ELI-3182 | Eliem Therapeutics | Preclinical | IPFAS | |
| Polafotisoran | Abbisko | Phase 2/3 | ALLLGS | |
| 117-9336 | Sino Biopharma | Phase 2/3 | Endometrial CaGastric Ca | |
| PRT-8732 | Prothena | Phase 2/3 | MMFL | |
| ALK-5502 | Alkermes | Phase 1 | Huntington's | |
| ENC-6986 | Encoded Ther | Approved | MCC | |
| Talazasiran | REGENXBIO | Approved | ADPKDAS | |
| JAN-1547 | Janux Ther | Approved | MDS | |
| BBI-9525 | Bridgebio | NDA/BLA | LGSHNSCC | |
| Polafutibatinib | Intercept (Alfasigma) | Preclinical | NASH | |
| SCR-9075 | Scribe Ther | NDA/BLA | Obesity | |
| Polatinib | Ikena Onc | Preclinical | MGPsoriasis | |
| Mirirasimod | Gloria Bio | NDA/BLA | PNHPV | |
| GEN-516 | Genkyotex (Calliditas) | Phase 2/3 | NBHCC | |
| REC-7914 | Recordati | NDA/BLA | Bladder CaAlzheimer's | |
| Doxazasiran | Acerus (Sun) | Phase 2/3 | PSPMelanoma | |
| MOR-3925 | Morphosys (Novartis) | Phase 1/2 | Myelofibrosis | |
| Talanesiran | Bayer AG | Preclinical | Pompe | |
| Zoritinib | Pierre Fabre | Approved | PBCADHD | |
| Ceviglumide | PharmaEngine | Phase 1 | Gastric CaCervical Ca | |
| Zenoinavolisib | Laboratorio Chile | NDA/BLA | Ovarian CaBladder Ca | |
| Rilusotorasib | Procaps Group | Preclinical | Breast CaEndometrial Ca | |
| APN-1617 | Aspen Pharmacare | Phase 2 | NSCLCHuntington's | |
| 300-8538 | Zhifei Biological | NDA/BLA | ADHDADPKD | |
| Tixainavolisib | Shanghai RAAS | Phase 3 | PVSchizophrenia | |
| Zanufotisoran | BioLife Solutions | Approved | NSCLC | |
| GR-6650 | Grünenthal | NDA/BLA | Parkinson'sCKD | |
| NEO-5524 | Neogen | Phase 1 | DLBCLMyelofibrosis | |
| 453-4974 | Santen Pharma | NDA/BLA | MSMCC |